vs

Side-by-side financial comparison of LEXICON PHARMACEUTICALS, INC. (LXRX) and Sound Financial Bancorp, Inc. (SFBC). Click either name above to swap in a different company.

Sound Financial Bancorp, Inc. is the larger business by last-quarter revenue ($9.5M vs $5.5M, roughly 1.7× LEXICON PHARMACEUTICALS, INC.). On growth, LEXICON PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (254.4% vs 1.5%). Over the past eight quarters, LEXICON PHARMACEUTICALS, INC.'s revenue compounded faster (124.2% CAGR vs 5.5%).

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its patented mouse gene knockout technology and extensive in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 1...

U.S. Bancorp is an American multinational banking institution headquartered in Minneapolis, Minnesota and incorporated in Delaware. It is the 5th-largest bank in the United States as of 2025. As the largest bank in the Midwestern United States, it is considered systemically important by the Financial Stability Board. It is the parent company of its primary operating entity, U.S. Bank National Association, which does business as U.S. Bank. The company provides banking, investment, mortgage, tr...

LXRX vs SFBC — Head-to-Head

Bigger by revenue
SFBC
SFBC
1.7× larger
SFBC
$9.5M
$5.5M
LXRX
Growing faster (revenue YoY)
LXRX
LXRX
+252.9% gap
LXRX
254.4%
1.5%
SFBC
Faster 2-yr revenue CAGR
LXRX
LXRX
Annualised
LXRX
124.2%
5.5%
SFBC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
LXRX
LXRX
SFBC
SFBC
Revenue
$5.5M
$9.5M
Net Profit
$-15.5M
Gross Margin
96.3%
Operating Margin
-269.1%
27.1%
Net Margin
-282.7%
Revenue YoY
254.4%
1.5%
Net Profit YoY
54.0%
EPS (diluted)
$-0.04
$0.87

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LXRX
LXRX
SFBC
SFBC
Q4 25
$5.5M
$9.5M
Q3 25
$14.2M
$9.8M
Q2 25
$28.9M
$10.4M
Q1 25
$1.3M
$9.2M
Q4 24
$1.6M
$9.4M
Q3 24
$1.7M
$9.1M
Q2 24
$1.6M
$8.6M
Q1 24
$1.1M
$8.6M
Net Profit
LXRX
LXRX
SFBC
SFBC
Q4 25
$-15.5M
Q3 25
$-12.8M
$1.7M
Q2 25
$3.3M
$2.1M
Q1 25
$-25.3M
$1.2M
Q4 24
Q3 24
$-64.8M
$1.2M
Q2 24
$-53.4M
$795.0K
Q1 24
$-48.4M
$770.0K
Gross Margin
LXRX
LXRX
SFBC
SFBC
Q4 25
96.3%
Q3 25
99.9%
Q2 25
99.9%
Q1 25
97.6%
Q4 24
77.5%
Q3 24
95.9%
Q2 24
89.7%
Q1 24
97.2%
Operating Margin
LXRX
LXRX
SFBC
SFBC
Q4 25
-269.1%
27.1%
Q3 25
-85.9%
21.3%
Q2 25
12.9%
24.5%
Q1 25
-2034.8%
15.9%
Q4 24
24.6%
Q3 24
-3658.4%
15.6%
Q2 24
-3423.3%
11.4%
Q1 24
-4147.6%
10.9%
Net Margin
LXRX
LXRX
SFBC
SFBC
Q4 25
-282.7%
Q3 25
-90.0%
17.3%
Q2 25
11.3%
19.8%
Q1 25
-2004.4%
12.7%
Q4 24
Q3 24
-3722.6%
12.7%
Q2 24
-3304.2%
9.2%
Q1 24
-4427.9%
9.0%
EPS (diluted)
LXRX
LXRX
SFBC
SFBC
Q4 25
$-0.04
$0.87
Q3 25
$-0.04
$0.66
Q2 25
$0.01
$0.79
Q1 25
$-0.07
$0.45
Q4 24
$0.74
Q3 24
$-0.18
$0.45
Q2 24
$-0.17
$0.31
Q1 24
$-0.20
$0.30

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LXRX
LXRX
SFBC
SFBC
Cash + ST InvestmentsLiquidity on hand
$96.2M
$138.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$107.5M
$109.4M
Total Assets
$185.0M
$1.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LXRX
LXRX
SFBC
SFBC
Q4 25
$96.2M
$138.5M
Q3 25
$116.0M
$101.2M
Q2 25
$139.0M
$102.5M
Q1 25
$194.8M
$131.5M
Q4 24
$238.0M
$43.6M
Q3 24
$258.4M
$148.9M
Q2 24
$310.0M
$135.1M
Q1 24
$355.6M
$138.0M
Stockholders' Equity
LXRX
LXRX
SFBC
SFBC
Q4 25
$107.5M
$109.4M
Q3 25
$120.2M
$107.5M
Q2 25
$129.4M
$106.0M
Q1 25
$123.0M
$104.4M
Q4 24
$145.9M
$103.7M
Q3 24
$178.5M
$102.2M
Q2 24
$240.0M
$101.3M
Q1 24
$288.9M
$101.0M
Total Assets
LXRX
LXRX
SFBC
SFBC
Q4 25
$185.0M
$1.1B
Q3 25
$205.9M
$1.1B
Q2 25
$225.6M
$1.1B
Q1 25
$297.7M
$1.1B
Q4 24
$298.4M
$993.6M
Q3 24
$321.1M
$1.1B
Q2 24
$373.4M
$1.1B
Q1 24
$417.2M
$1.1B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LXRX
LXRX
SFBC
SFBC
Operating Cash FlowLast quarter
$-17.2M
$7.2M
Free Cash FlowOCF − Capex
$7.0M
FCF MarginFCF / Revenue
73.4%
Capex IntensityCapex / Revenue
1.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$12.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LXRX
LXRX
SFBC
SFBC
Q4 25
$-17.2M
$7.2M
Q3 25
$-23.8M
$3.8M
Q2 25
$17.0M
$-494.0K
Q1 25
$-43.8M
$1.9M
Q4 24
$-178.8M
$2.9M
Q3 24
$-53.6M
$3.3M
Q2 24
$-48.5M
$-4.0M
Q1 24
$-55.1M
$3.5M
Free Cash Flow
LXRX
LXRX
SFBC
SFBC
Q4 25
$7.0M
Q3 25
$3.8M
Q2 25
$-518.0K
Q1 25
$1.8M
Q4 24
$-179.8M
$2.9M
Q3 24
$-53.9M
$3.2M
Q2 24
$-48.8M
$-5.6M
Q1 24
$1.9M
FCF Margin
LXRX
LXRX
SFBC
SFBC
Q4 25
73.4%
Q3 25
38.3%
Q2 25
-5.0%
Q1 25
19.8%
Q4 24
-11600.7%
30.4%
Q3 24
-3097.4%
35.5%
Q2 24
-3017.3%
-65.4%
Q1 24
22.2%
Capex Intensity
LXRX
LXRX
SFBC
SFBC
Q4 25
1.8%
Q3 25
0.0%
0.4%
Q2 25
0.2%
Q1 25
0.4%
Q4 24
66.5%
0.8%
Q3 24
17.6%
0.5%
Q2 24
15.5%
18.7%
Q1 24
0.0%
19.0%
Cash Conversion
LXRX
LXRX
SFBC
SFBC
Q4 25
Q3 25
2.24×
Q2 25
5.23×
-0.24×
Q1 25
1.59×
Q4 24
Q3 24
2.84×
Q2 24
-5.05×
Q1 24
4.57×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons